Methods for treating cancer by modulating &bgr;-catenin mediated gene expression
US6677116B1 · kind B1 · utility
5Cited by
4References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 14, 2000 |
| Grant date | Jan 13, 2004 |
| Priority date | — |
| Expiry date | Apr 14, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Modulating agents for inhibiting &bgr;-catenin mediated gene expression are provided. The modulating agents comprise one or more of: (1) the peptide sequence LXXLL (SEQ ID NO:1); or (2) a peptide analogue or peptidomimetic thereof. Methods for using such modulating agents for modulating &bgr;-catenin mediated gene expression and cellular differentiation in a variety of contexts (e.g., for modulating hair growth or treating cancer or Alzheimer's disease) are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.